Efficacy of a Recombinant Humanized Anti-IL-6 Receptor Monoclonal Antibody Compared to Hemoperfusion in Severe COVID-19 Pneumonia: Ambispective Cohort Study

被引：0
|
作者：
Thammavaranucupt, Kanin [1 ]
Jayanama, Kulapong [1 ]
Spanuchart, Ittikorn [2 ]
机构：
[1] Chakri Naruebodin Med Inst, Bang Phli, Thailand
[2] Mahidol Univ, Fac Med, Ramathibodi Hosp, Bangkok, Thailand
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
FR-PO016
引用
收藏
页码：330 / 330
页数：1
相关论文
共 50 条
  • [1] Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia
    Ulhaq, Zulvikar Syambani
    Soraya, Gita Vita
    MEDICINA CLINICA, 2020, 155 (12): : 548 - 556
  • [2] Tocilizumab - A humanized anti-IL-6 receptor monoclonal antibody for the treatment of rheumatoid arthritis
    Schlesselman, Lauren S.
    Hussey, Aaron P.
    FORMULARY, 2008, 43 (08) : 272 - 279
  • [3] In Vitro Cellular Profiling of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Reveals a Distinct Phenotypic Signature Compared to Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody
    Chavele, Konstantia-Maria
    Gardner, Debbie
    Loza, Matthew J.
    Dasgupta, Bidisha
    Sims, Martin
    Shealy, David
    Reid, Juliet
    Rao, Ravi
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis
    Ohsugi, Yoshiyuki
    Kishimoto, Tadamitsu
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (05) : 669 - 681
  • [5] Clinical Efficacy of Anti-IL-6 Receptor Monoclonal Antibody Tocilizumab in Patients with Neuromyelitis Optica
    Araki, Manabu
    Matsuoka, Takako
    Aranami, Toshimasa
    Nakamura, Masakazu
    Okamoto, Tomoko
    Murata, Miho
    Miyake, Sachiko
    Yamamura, Takashi
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 911 - 912
  • [6] Clinical efficacy of anti-IL-6 receptor monoclonal antibody tocilizumab for the treatment of neuromyelitis optica
    Araki, M.
    Matsuoka, T.
    Aranami, T.
    Nakamura, M.
    Okamoto, T.
    Murata, M.
    Miyake, S.
    Yamamura, T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 947 - 947
  • [7] Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19
    Parums, Dinah V.
    MEDICAL SCIENCE MONITOR, 2021, 27
  • [8] Clinical efficacy of anti-IL-6 receptor monoclonal antibody tocilizumab in three patients with neuromyelitis optica
    Araki, M.
    Aranami, T.
    Matsuoka, T.
    Nakamura, M.
    Okamoto, T.
    Murata, M.
    Miyake, S.
    Yamamura, T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 417 - 417
  • [9] Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study
    Araki, Manabu
    Matsuoka, Takako
    Miyamoto, Katsuichi
    Kusunoki, Susumu
    Okamoto, Tomoko
    Murata, Miho
    Miyake, Sachiko
    Aranami, Toshimasa
    Yamamura, Takashi
    NEUROLOGY, 2014, 82 (15) : 1302 - 1306
  • [10] Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
    Zhao, Ming
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (06)
12345